FRATES JAMES M 4/A
4/A · Amylyx Pharmaceuticals, Inc. · Filed Sep 5, 2024
Insider Transaction Report
Form 4/AAmended
FRATES JAMES M
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-08-23$6.88/sh+18,165$124,975→ 73,841 total - Exercise/Conversion
Stock Option (right to buy)
2023-08-23−18,165→ 363,835 totalExercise: $6.88Exp: 2031-01-25→ Common Stock (18,165 underlying)
Holdings
- 19,482(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]On August 24, 2023, a Form 4 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 5 of Table I by 32,500 shares due to an administrative error. This Form 4 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date, as well as the corresponding amounts that were carried forward on Form 4 reports subsequently filed on behalf of the Reporting Person.
- [F2]Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F3]113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.